Formycon AG logo

FYB - Formycon AG News Story

€31.4 -2.7  -7.9%

Last Trade - 5:36pm

Sector
Healthcare
Size
Small Cap
Market Cap £308.4m
Enterprise Value £290.1m
Revenue £35.3m
Position in Universe 515th / 1054

BRIEF-Formycon And Bioeq Enroll First Patient In Phase III Study With Aflibercept Biosimilar

Mon 24th August, 2020 6:03am
Aug 24 (Reuters) - Formycon AG  FYB.DE :
    * FORMYCON AND BIOEQ ENROLL FIRST PATIENT IN PHASE III STUDY
WITH
AFLIBERCEPT BIOSIMILAR (FYB203)

Source text for Eikon:  ID:nEQ7Yk097a 
Further company coverage:  FYB.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.